富联娱乐

Be the most trusted biotech company

2022-12-02

The Updated Results of Phase 3 Clinical Study of Novel Anti-PD-1 mAb Serplulimab for the First-Line Treatment of ES-SCLC Released at ESMO Asia Congress 2022
2022-12-02

First Subject Dosed for Phase 1 Clinical Trial of Henlius’ Novel Anti-GARP mAb HLX60
2022-11-29

First Patient dosed in a Head-to-Head First-Line Bridging Study of HANSIZHUANG for ES-SCLC treatment in the US
2022-11-24

Henlius’ Phase 3 Clinical Studies of Novel Anti-PD-1 mAb Serplulimab for the First-Line Treatment of ES-SCLC and ESCC will be Presented at ESMO Asia Congress 2022
2022-11-18

The CTA of Anti-PD-1 mAb Serplulimab for MRCT Phase 3 Studies on First-Line LS-SCLC Patients Approved in EU
2022-11-11

The IND Application of Phase 1b/2 Clinical Trial of BARF V600E Inhibitor HLX208 in Combination with HANSIZHUANG for the Treatment of BARF V600 Mutation-Positive Solid Tumours was Approved by the NMPA
2022-11-09

Henlius' Innovative Asymmetric Bispecific Antibody CLD Platform Published in Biochemical Engineering Journal
2022-11-04

Henlius Wins Generics Bulletin ‘Business Development of the Year’ Award
2022-11-01

Henlius' Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Receives NMPA Approval for the Treatment of sqNSCLC